In NRG Oncology/RTOG 1010, HER2‐targeted escalation did not improve survival or patient‐reported outcomes in localized esophageal adenocarcinoma. The study illustrates that biologic plausibility and metastatic success do not guarantee benefit in the curative‐intent setting and emphasizes the need for rigorous, patient‐...
T. J. Brown, N. Hornstein, U. Grewal et al.· Cancer· 0 citations
Abstract RAF1 alterations are rare in metastatic colorectal cancer (mCRC), occurring in roughly 0.5% of cases, and lack established treatment guidance. We present a patient with RAF1 S257L–mutated, RAS wild-type mCRC and concurrent type 1 Gaucher disease, whose baseline cytopenias precluded standard chemotherapy and cl...
A. Rose, Alix Rosenberg, U. Grewal et al.· The Oncologist· 0 citations
Background Cholangiocarcinoma (CCA) is an aggressive biliary malignancy with increasing incidence and poor prognosis. Although traditionally considered a disease of older adults, early-onset CCA (EOCCA; age <50 years) may represent a clinically distinct subgroup. Data evaluating diagnostic and treatment trajectories in...
U. Grewal, A. Nottke, B. Loeffler et al.· ESMO gastrointestinal oncolo...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.